Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

Peter Richmond, H.S. Marshall, M.D. Nissen, Q. Jiang, K.U. Jansen, M. Garcés-Sánchez, F. Martinón-Torres, J. Beeslaar, L. Szenborn, J. Wysocki, J. Eiden, S.L. Harris, T.R. Jones, J.L. Perez

    Research output: Contribution to journalArticlepeer-review

    114 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)597-607
    JournalThe Lancet Infectious Diseases
    Issue number8
    Publication statusPublished - 2012

    Cite this